MorphImmune
About:
MorphImmune is a preclinical biotechnology company that targets small-molecule therapeutics.
Website: https://www.morphimmune.com/
Description:
Morphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases the efficacy of known effector molecules, ultimately improving outcomes for patients.
Total Funding Amount:
$32.1M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
West Lafayette, Indiana, United States
Founded Date:
2020-01-01
Founders:
Philip Low
Number of Employees:
1-10
Last Funding Date:
2023-05-16
IPO Status:
Private
Industries:
© 2025 bioDAO.ai